SymBio Pharmaceuticals Limited [4582.T]
TOKYO, Jun 09 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582.T) completed the first patient registration (First Patient In) for its Phase I clinical trial of intravenous brincidofovir (IV BCV) aimed at treating progressive multifocal leukoencephalopathy (PML). The trial, conducted at the National Institutes of Health's Clinical Center in Bethesda, Maryland, led by Dr.
Irene Cortese, seeks to evaluate the efficacy and safety of IV BCV in PML patients. PML is a severe brain disease caused by JC virus infection of the central nervous system, with high mortality rates among immunocompromised individuals.
There is currently no established standard treatment, making the development of new therapies highly anticipated. President and CEO Fumiki Yoshida commented, “We are delighted to collaborate with NIH/NINDS on developing treatments for untapped areas such as PML.
Alongside our multiple sclerosis drug development efforts, we aim to actively expand our presence in neurodegenerative diseases.” The completion of the first patient registration does not impact the company’s fiscal year ending December 2026 earnings forecast.
🟢 Confidence: High AI-translated content.